We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+3.51%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.75B
AUM Growth
-$295K
(-0.02%)
Cap. Flow
-$6.43M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
42.15%
Holding
44
New
7
Increased
10
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$50.5M |
| 2 |
Zimmer Biomet
ZBH
|
+$49.2M |
| 3 |
AET
Aetna Inc
AET
|
+$48.7M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$28.6M |
| 5 |
GoDaddy
GDDY
|
+$28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$60M |
| 2 |
GRUB
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
|
+$43.1M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$35.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$33.7M |
| 5 |
DexCom
DXCM
|
+$32.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.31% |
| 2 | Consumer Discretionary | 11.47% |
| 3 | Communication Services | 7.33% |
| 4 | Technology | 7.04% |
| 5 | Financials | 6.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDCO
1
DELISTED
Medicines Co
MDCO
| $93.6M | 5.34% |
2,461,240
+642,752
| +35% | +$28.6M |
|
2
Post Holdings
POST
$4.17B
| $91M | 5.2% |
1,791,528
+153,405
| +9% | +$8.27M |
|
|
3
GoDaddy
GDDY
$10.5B
| $86.4M | 4.93% |
2,036,589
+700,000
| +52% | +$28M |
|
|
EVHC
4
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $83.8M | 4.78% |
1,336,479
-82,604
| -6% | -$4.76M |
|
|
SHPG
5
DELISTED
Shire pic
SHPG
| $77.4M | 4.41% |
468,130
-84,847
| -15% | -$14.8M |
|
|
SGI
6
Somnigroup International
SGI
$13.9B
| $66M | 3.76% |
4,942,172
+1,410,160
| +40% | +$16.6M |
|
7
Gilead Sciences
GILD
$161B
| $65.2M | 3.72% |
921,797
-103,978
| -10% | -$6.92M |
|
8
Alnylam Pharmaceuticals
ALNY
$27.3B
| $60.5M | 3.46% |
759,127
+32,036
| +4% | +$2.05M |
|
9
Armstrong World Industries
AWI
$7.32B
| $57.6M | 3.29% |
1,251,456
| – | – |
|
10
Labcorp
LH
$25.1B
| $57.2M | 3.27% |
432,264
-24,868
| -5% | -$3.05M |
|
11
Nektar Therapeutics
NKTR
$2.37B
| $55M | 3.14% |
187,406
-8,411
| -4% | -$2.43M |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $54.2M | 3.09% |
222,896
-56,903
| -20% | -$13.4M |
|
13
Morgan Stanley
MS
$333B
| $53.9M | 3.08% |
1,210,359
+300,000
| +33% | +$12.9M |
|
14
Caesars Entertainment
CZR
$6.04B
| $53.9M | 3.08% |
2,695,132
+1,059,154
| +65% | +$21.2M |
|
|
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
| $52.6M | 3% |
1,915,076
-740,180
| -28% | -$20.9M |
|
|
AET
16
DELISTED
Aetna Inc
AET
| $52.3M | 2.98% |
+344,409
| New | +$48.7M |
|
|
17
Zimmer Biomet
ZBH
$18B
| $51.8M | 2.95% |
+415,253
| New | +$49.2M |
|
18
Humana
HUM
$44.5B
| $51.6M | 2.94% |
214,336
-60,572
| -22% | -$13.7M |
|
|
19
Merck
MRK
$322B
| $50.8M | 2.9% |
+829,910
| New | +$50.5M |
|
20
Meta Platforms (Facebook)
META
$1.39T
| $48.5M | 2.77% |
321,505
| – | – |
|
21
TG Therapeutics
TGTX
$8.01B
| $46.7M | 2.66% |
4,645,265
+22,516
| +0.5% | +$252K |
|
22
Charter Communications
CHTR
$17.3B
| $46.5M | 2.65% |
138,087
| – | – |
|
23
Incyte
INCY
$24.2B
| $46.3M | 2.64% |
368,034
+90,360
| +33% | +$11.5M |
|
24
VeriSign
VRSN
$26.1B
| $36.9M | 2.11% |
397,036
-88,000
| -18% | -$7.95M |
|
25
Adient
ADNT
$1.59B
| $34.5M | 1.97% |
527,133
| – | – |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q2 2017 Portfolio in Review
As of Q2 2017, Bridger Management held 44 positions worth $1.75B, down 0.02% from $1.75B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bridger Management's Q2 2017 filing shows 7 new, 10 increased, 13 reduced and 7 closed positions. Its largest new stake was Merck: 829,910 shares worth $50.8M. The largest sale was Centene, an estimated $60M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Bridger Management's largest Q2 2017 buy was Merck: 829,910 shares worth $50.8M.
- Bridger Management added most to Medicines Co in Q2 2017, an estimated $28.6M increase.
- Bridger Management's biggest Q2 2017 reduction was Teva Pharmaceuticals, cutting an estimated $33.7M.
- Bridger Management fully exited Centene in Q2 2017, selling an estimated $60M.
- Bridger Management's ten largest holdings make up 42% of its $1.75B portfolio in Q2 2017.
- Bridger Management opened 7 new positions and closed 7 in Q2 2017.
- Bridger Management's portfolio value fell 0.02% quarter-over-quarter to $1.75B.
Based on Bridger Management's 13F filing for Q2 2017, filed 14 Aug 2017.